机译:酪氨酸激酶抑制剂用于治疗放射性碘难治性,转移性或复发性和进行性分化型甲状腺癌
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Clinical Trial Management Center, Department of Surgery, Kuma Hospital, Kobe, Japan;
Chairperson of Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Thyroid and Endocrinology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Division of Breast, Endocrine and Respiratory Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,National Hospital Organization, Higashinagoya National Hospital, Nagoya, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Surgery Ⅱ, Tokyo Women's Medical University, Tokyo, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Otolaryngology, Tottori University School of Medicine, Yonago, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Endocrine Surgery, Nippon Medical School, Tokyo, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Surgery, Ito Hospital, Tokyo, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Chest and Thyroid Surgery, Tokyo Medical University, Tokyo, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Kanagawa Health Service Association, Yokohama, Japan;
Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan ,Department of Endocrine Surgery, Nippon Medical School, Tokyo, Japan;
Differentiated thyroid cancer; TKI therapy; Adverse events;
机译:酪氨酸激酶抑制剂治疗放射性碘难治性,转移性或复发性和进行性分化型甲状腺癌[综述]
机译:利用甲状腺球蛋白的早期检测迁移型甲状腺素倍增时间,放射性碘处理甲状腺癌
机译:淋巴细胞对单核细胞比例对索拉芬布治疗的渐进式放射性偶联分化甲状腺癌患者临床结果的预后作用(VOL 92,PG 71,2020)
机译:何时治疗转移性肾细胞癌的组合,全身治疗,以及在转移性肾癌中的活跃监测
机译:维甲酸,组蛋白脱乙酰基酶抑制剂和胚胎癌干细胞分化。
机译:来伐替尼和索拉非尼用于放射性碘治疗后进行性局部晚期或转移性分化型甲状腺癌的系统评价
机译:编辑评论对先前用血管内皮生长因子受体酪氨酸激酶抑制剂和哺乳动物抑制剂的哺乳动物靶标的转移性肾细胞癌患者的Assitinib活动